Less than 10% of patients who could benefit from GLP-1 drugs such as Wegovy can access them, states the WHO as it issues its inaugural advice on the drugs.
Considering more than one billion individuals worldwide currently living with obesity, it is calling for more widespread and fairer availability to GLP-1 medication.
According to projections, over two billion could be living with obesity by 2030 without intervention.
"Our latest guidance recognises that obesity is a lifelong illness that can be treated with comprehensive and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant hurdles to universal availability to the injections that can aid individuals in losing significant body mass, says the body.
Skinny Jab Supply Crisis
Despite the present most favorable scenario, the manufacturing of such drugs could only cover about 100 million people – less than 10% of eligible patients, according to the health organization.
The advice calls on nations and manufacturers to expand availability, by approaches such as voluntary licensing.
Exclusive production rights on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Jabs Function
The injections replicate a biological compound to reduce digestion speed, reduce hunger and boost the sense of being full so people reduce food intake.
Patients typically start to lose weight after several weeks of commencing the weekly injections.
Studies points to patients may see weight return within a year of halting the treatment, because their usual hunger come back.
Being above a healthy weight increases your likelihood for contracting medical conditions, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity impacts people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
